Prelude Therapeutics
PRLD
50 hedge funds and large institutions have $22M invested in Prelude Therapeutics in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 17 closing their positions.
7.2% less ownership
Funds ownership: 55.36% → 48.15% (-7.2%)
15% less funds holding
Funds holding: 59 → 50 (-9)
18% less capital invested
Capital invested by funds: $26.9M → $22M (-$4.93M)
48% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 23
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
+$183K |
| 2 |
Millennium Management
New York
|
+$88K |
| 3 |
Jane Street
New York
|
+$79.4K |
| 4 |
SC
Shay Capital
New York
|
+$64.9K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$61.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.62M |
| 2 |
BCM
Boxer Capital Management
San Diego,
California
|
-$1.62M |
| 3 |
BlackRock
New York
|
-$533K |
| 4 |
State Street
Boston,
Massachusetts
|
-$163K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$162K |
PRLD Hedge Fund Activity: Q2 2025 in Review
50 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q2 2025, worth a combined $22M — down 18% from $26.9M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of PRLD and 8 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 12 added.
The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $183K. The largest seller was Nuveen, exiting entirely with an estimated $3.62M sold.
- 50 institutional investors held Prelude Therapeutics (PRLD) as of Q2 2025, down from 59 in Q1 2025.
- Funds reported $22M of Prelude Therapeutics stock for Q2 2025, down 18% quarter-over-quarter.
- 8 funds opened new Prelude Therapeutics positions in Q2 2025 and 17 closed out, a net change of -9 holders.
- The largest Prelude Therapeutics buyer in Q2 2025 was Cantor Fitzgerald, an estimated $183K added.
- The largest Prelude Therapeutics seller in Q2 2025 was Nuveen, an estimated $3.62M sold.
Based on aggregated 13F filings for Q2 2025.